22 Sep Oculis to present recent milestones at key biotech and ophthalmology conferences
Oculis to present significant corporate and clinical development progress at upcoming biotech and ophthalmology conferences
LAUSANNE, Switzerland, September 22, 2020
Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announced that Dr. Marcia de Souza Lima, Chief Medical Officer, will present at a number of upcoming virtual industry conferences – see below.
At these events, Dr. de Souza Lima will provide an overview of Oculis’ portfolio and the significant progress it has made during 2020 with the advancement of its lead candidates OCS-01 and OCS-02.
A key focus of the presentations will be on the development of OCS-01 as a potentially transformative and first topical treatment for Diabetic Macular Edema (DME) and as the first once a day steroid for the treatment of inflammation and pain following ocular surgery. Positive clinical results from Phase 2 trials of OCS-01 in both indications were announced in February and May, respectively. The Company is now designing Phase 3 programs in both indications based on these results together with positive feedback received recently from the U.S. Food and Drug Administration (FDA) from an End-of-Phase 2 meeting. These trials are expected to start in the first half of 2021.
Dr. de Souza Lima will also discuss the results of Phase 2 proof-of-concept studies with OCS-02, a topical anti-TNF alpha, and potentially the first-in-class steroid-sparing treatment for Anterior Uveitis and Dry Eye Disease. It may also open the doors to personalized treatment for Dry Eye Syndrome, based on the identification of a potential genetic biomarker of treatment response.
“This is certainly an exciting time for Oculis with multiple clinical and regulatory milestones being reached. This positive progress has given us the confidence to proceed with the expansion of our leadership team with the appointment of several key executives and with the incorporation of Oculis Inc. in the U.S., for the effective implementation of the Company’s growth strategy,” commented Riad Sherif, CEO
Presentations will be made at:
- Sachs 20th Annual Biotech in Europe Forum for Global Partnering and Investment – September 21-24
- OIS European Innovation Showcase – September 23
- Ophthalmology Futures Forum – September 30 – October 1
- Bio-Europe Digital – October 26-29
Dr. Riad Sherif, CEO
Louie-Anne Gauthier, VP Strategic Marketing, BD&L
Citigate Dewe Rogerson
Mark Swallow / Sylvie Berrebi
+44 7903 737703 / +44 7714 306525